Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul/Aug;26(4):281-286.
doi: 10.1097/PPO.0000000000000455.

Price, Cost, and Value of Cancer Medicines: A Pharmaceutical Industry Perspective

Mace L Rothenberg  1 , Justin McCarthy, Patrick Holmes
Affiliations
Review

Price, Cost, and Value of Cancer Medicines: A Pharmaceutical Industry Perspective

Mace L Rothenberg et al. Cancer J. 2020 Jul/Aug.

Abstract

More than 1.8 million cancer diagnoses will be made in 2020 driving substantial health and economic burden for patients. The financial impact of out-of-pocket payments for hospital stays, outpatient services, physician appointments, and prescription drugs is a particular challenge. At the same time, the treatment of cancer is undergoing substantial transformation with growing benefits for patients. The complex factors contributing to the economic burden must be addressed so that patients have broad access to innovative oncology medicines both today and tomorrow. There are 2 parallel actions that are needed to drive broad reductions in costs while not putting at risk the incredible potential innovation awaiting these same patients: (i) the private sector must work together across the health care sector to accelerate innovative value-based partnerships; and (2) policymakers need to drive policy reforms that help ease out-of-pocket costs and remove barriers to and enable scaling of value-based care.

PubMed Disclaimer

References

    1. IQVIA Institute. Global Oncology Trends 2019. May 2019. Available at: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncolo.... Accessed April 7, 2020.
    1. Soda M, Choi Y, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non–small-cell lung cancer. Nature. 2007;448:561–566.
    1. Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. N Engl J Med. 2010;363:1693–1703.
    1. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247–4253.
    1. Sivignon M, Monnier R, Tehard B, et al. Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non–small-cell lung cancer in France. PLoS One. 2020;15:e0226196.

LinkOut - more resources